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RESEARCH
Omega-3, omega-6, and total dietary polyunsaturated fat for 
prevention and treatment of type 2 diabetes mellitus: systematic 
review and meta-analysis of randomised controlled trials
Tracey J Brown*, Julii Brainard*, Fujian Song, Xia Wang, Asmaa Abdelhamid, Lee Hooper,  
on behalf of the PUFAH Group
ABSTRACT
OBJECTIVE
To assess effects of increasing omega-3, omega-6, 
and total polyunsaturated fatty acids (PUFA) on 
diabetes diagnosis and glucose metabolism.
DESIGN
Systematic review and meta-analyses.
DATA SOURCES
Medline, Embase, Cochrane CENTRAL, WHO International 
Clinical Trials Registry Platform, Clinicaltrials.gov, and 
trials in relevant systematic reviews.
ELIGIBILITY CRITERIA
Randomised controlled trials of at least 24 weeks’ 
duration assessing effects of increasing α-linolenic 
acid, long chain omega-3, omega-6, or total PUFA, 
which collected data on diabetes diagnoses, fasting 
glucose or insulin, glycated haemoglobin (HbA1c), 
and/or homoeostatic model assessment for insulin 
resistance (HOMA-IR).
DATA SYNTHESIS
Statistical analysis included random effects meta-
analyses using relative risk and mean difference, and 
sensitivity analyses. Funnel plots were examined and 
subgrouping assessed effects of intervention type, 
replacement, baseline risk of diabetes and use of 
antidiabetes drugs, trial duration, and dose. Risk of 
bias was assessed with the Cochrane tool and quality 
of evidence with GRADE.
RESULTS
83 randomised controlled trials (mainly assessing 
effects of supplementary long chain omega-3) were 
included; 10 were at low summary risk of bias. Long 
chain omega-3 had little or no effect on likelihood 
of diagnosis of diabetes (relative risk 1.00, 95% 
confidence interval 0.85 to 1.17; 58 643 participants, 
3.7% developed diabetes) or measures of glucose 
metabolism (HbA1c mean difference −0.02%, 95% 
confidence interval −0.07% to 0.04%; plasma glucose 
0.04, 0.02 to 0.07, mmol/L; fasting insulin 1.02, 
−4.34 to 6.37, pmol/L; HOMA-IR 0.06, −0.21 to 0.33). 
A suggestion of negative outcomes was observed 
when dose of supplemental long chain omega-3 was 
above 4.4 g/d. Effects of α-linolenic acid, omega-6, 
and total PUFA on diagnosis of diabetes were unclear 
(as the evidence was of very low quality), but little 
or no effect on measures of glucose metabolism was 
seen, except that increasing α-linolenic acid may 
increase fasting insulin (by about 7%). No evidence 
was found that the omega-3/omega-6 ratio is 
important for diabetes or glucose metabolism.
CONCLUSIONS
This is the most extensive systematic review of trials 
to date to assess effects of polyunsaturated fats on 
newly diagnosed diabetes and glucose metabolism, 
including previously unpublished data following 
contact with authors. Evidence suggests that 
increasing omega-3, omega-6, or total PUFA has little 





Type 2 diabetes mellitus is a leading cause of death and 
increases risks of cardiovascular disease, blindness, 
kidney failure, and lower limb amputation.1 More than 
400 million adults worldwide live with diabetes. This 
figure is rising,1 2 causing excess mortality, morbidity, 
and substantial economic cost. The global annual 
cost of diabetes is estimated at more than $800bn 
(£636bn; €709bn) and is increasing.1 3 Type 2 diabetes 
mellitus occurs as glycaemic control worsens leading 
to dyslipidaemia (higher triglycerides and lower 
concentrations of high density lipoprotein cholesterol) 
and is due to defects in production and/or action of 
insulin.4 5 The global rise in diabetes can be attributed 
mainly to increased body fatness and inactivity,1 6 so 
diet and body weight are key in treating, preventing, 
and delaying onset of type 2 diabetes mellitus.1
Polyunsaturated fatty acids (PUFA) include omega-3, 
omega-6, and omega-9 fats. Omega-3 fats include 
long chain omega-3 fats such as eicosapentaenoic 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Effects of omega-3, omega-6, and total polyunsaturated fatty acids on glucose 
metabolism and type 2 diabetes diagnosis are inconclusive
Experimental data have suggested that omega-3 worsens control of diabetes, 
and systematic reviews of observational studies suggest both benefit and harm
Omega-6 has been theorised to oppose effects of omega-3, and observational 
data have associated higher omega-6 with both improvement and worsening of 
glucose metabolism
WHAT THIS STUDY ADDS
Increasing long chain omega-3 had little or no effect on likelihood of diagnosis 
of diabetes or on glucose metabolism, with no difference by duration, baseline 
glucose metabolism, or nutrients replaced
There was a suggestion that high dose supplementation (>4.4 g/d) with long 
chain omega-3 may worsen glucose metabolism
Increasing α-linolenic acid, omega-6, and total polyunsaturated fatty acids had 
little or no effect on glucose metabolism, except that increasing α-linolenic acid 
may increase fasting insulin by about 7%
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acid and docosahexaenoic acid, commonly found 
in fish, and α-linolenic acid found in some plant 
oils (including flaxseed and rapeseed or canola). 
Many plant oils are rich in omega-6 fats, particularly 
linoleic acid. The UK government recommends that 
all adults should consume 6.5% of energy as PUFA 
and suggests eating a portion of oily fish each week 
(providing ~0.45 g/d long chain omega-3) but limiting 
oily fish in pregnancy and lactation owing to potential 
methylmercury contamination; supplements are not 
recommended.7-9 The American Diabetes Association 
endorses a Mediterranean-style diet high in poly-
unsaturates, long chain omega-3, and α-linolenic 
acid without supplements.10 Oily fish intake, but not 
supplementation, is also recommended in UK patients 
with type 2 diabetes mellitus, and reduction of total 
and saturated fat is recommended for prevention of 
diabetes, replacing saturated with polyunsaturated 
fats.10 11 The American Heart Association recommends 
supplementation for adults not eating enough oily 
fish.12 The Global Burden of Disease Study suggests 
that optimal omega-6 intake is 11% of energy, although 
global intakes average under 5% of energy intake; 
optimal intake of long chain omega-3 is 0.25 g/d, 
and mean global intake is 0.10 g/d.13 Despite the 
consistency of advice to eat oily fish, oily fish intakes in 
the UK have been stable for a decade at less than half 
of recommended levels.14 15 US adults’ intakes of long 
chain omega-3 are higher from dietary supplements 
(0.72 g/d eicosapentaenoic acid and docosahexaenoic 
acid) than from foods (0.41 g/d).16
Worries about effects of long chain omega-3 on 
control of diabetes have long existed, and experimental 
studies suggest that omega-3 supplementation and 
diets high in PUFA and omega-3 raise fasting glucose 
significantly.17 18 Methylmercury and polychlorinated 
biphenyl levels exceeding recommended thresholds 
have been reported in seafoods and fish oil 
supplements8 19 20; elevated mercury levels interrupt 
insulin signalling, raising fasting glucose, in mouse 
models.21 Body concentrations of organic pollutants 
are correlated with prevalence of diabetes in the 
US,22 but other cross sectional studies have suggested 
either no association with or benefits of eating fish 
on glycaemic control.23 24 Systematic reviews of 
observational studies have suggested both positive and 
negative associations with glucose metabolism,25-28 
but strong evidence shows that omega-3 supplements 
reduce raised triglycerides and have little or no effect 
on body weight.29 Although analysis of Global Burden 
of Disease data suggests that both long chain omega-3 
and omega-6 need to be increased globally, theories 
suggest that omega-3 and omega-6 fats compete 
in some metabolic pathways so that the omega-3/
omega-6 ratio is more important than absolute 
intakes of either.30 A Cochrane systematic review 
assessed effects of omega-3 in people with diabetes, 
including trials randomising 1075 participants in 23 
trials for a mean of nine weeks, finding reductions in 
triglycerides but no changes in glycated haemoglobin 
(HbA1c), fasting glucose, or insulin.
31 A more recent 
review included 1209 participants with diabetes in 
20 randomised controlled trials of at least two weeks’ 
duration and found little effect apart from an almost 
statistically significant rise in fasting glucose but little 
or no effect on HbA1c.
32
Long term effects of PUFA on development and 
treatment of diabetes remain inconclusive. We aimed 
to systematically review effects of PUFA (long chain 
omega-3, α-linolenic acid, omega-6, total PUFA) on 
diabetes outcomes including diagnoses of diabetes 
and pre-diabetes and markers of glucose regulation 
(serum glucose, HbA1c, insulin resistance). We were 
also interested in how effects varied by intervention 
type, baseline glucose metabolism, dose, duration, and 
nutrients displaced by increased PUFA. This review is 
part of a series by the PUFAH Group commissioned by 
the World Health Organization’s Nutrition Guidance 
Expert Advisory Group (NUGAG) Subgroup on Diet and 
Health to inform and contribute to the development of 
updated WHO recommendations. The full set of reviews 
assesses effects of PUFA on cardiovascular disease, 
cancers, inflammatory bowel disease, neurocognitive 
outcomes, musculoskeletal and functional outcomes, 
and depression.29 33-38
Methods
This systematic review is registered on PROSPERO.39 
Methods for the set of PUFAH reviews were based 
on Cochrane and GRADE,40 41 using RevMan and 
GradePRO software. Detailed methods for the set of 
reviews, the trials database, and flow diagrams are 
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described elsewhere.36 The review method is briefly 
presented here.
Inclusion criteria
We included published and unpublished randomised 
controlled trials comparing higher with lower omega-3, 
omega-6, and/or total PUFA intake for at least 24 weeks 
that assessed our primary outcomes. Participants 
were adults (aged ≥18 years) at any risk of diabetes, 
including healthy adults and those with diagnosed 
diabetes, but we excluded trials of pregnant or acutely 
ill participants. Eligible interventions could be dietary 
advice, supplementation (taken orally as oil, foods, or 
capsules), or diet provided. If no clear aim to increase 
PUFA was stated, but it was implied, the intervention 
had to achieve an increase or decrease of at least 10% 
of baseline PUFA level. As total dose of PUFA (PUFA 
dose in intervention minus PUFA dose in control) 
was difficult to establish reliably in most studies 
owing to poor reporting of control interventions, we 
included studies in the higher versus lower total PUFA 
comparison only when the trial aimed to increase total 
PUFA or aimed to increase both omega-3 and omega-6 
in the intervention compared with the control group. We 
excluded multifactorial interventions. Primary outcomes 
included new diagnosis of diabetes, new diagnosis of 
pre-diabetes (eg, impaired fasting glucose, impaired 
glucose tolerance, or impaired glucose regulation), 
glycaemic control (serum or plasma glucose, HbA1c), 
serum insulin, and insulin resistance (homoeostatic 
model assessment for insulin resistance (HOMA-IR)).
Methods for identification of studies
We searched Cochrane CENTRAL, Medline, and 
Embase to 27 April 2017 and ClinicalTrials.com and 
the WHO International Clinical Trials Registry Platform 
to September 2016, and we reassessed all ongoing 
trials in December 2018. We checked included trials 
of relevant systematic reviews and wrote to authors of 
included studies for additional studies and trial data, 
as described in detail elsewhere,36 creating a database 
of trials that randomised participants to increased 
omega-3, omega-6, or total PUFA compared with lower 
omega-3, omega-6, or total PUFA and assessed effects 
for at least 24 weeks (reflecting metabolic studies 
suggesting that six months is the minimum duration 
of supplementation needed to ensure equilibration of 
long chain omega-3 into most body compartments).42 
From this database, we chose studies for this review 
that had assessed at least one primary review outcome 
(even when not fully reported).
Study inclusion, data extraction, and assessment of 
risk of bias were conducted independently in duplicate. 
We assessed Cochrane risk of bias tool domains,43 as 
well as assessing risk from compliance problems and 
attention bias, specific to our set of reviews.36 We 
considered trials to be at low summary risk of bias if 
we judged randomisation, allocation concealment, 
and blinding of participants, personnel, and outcome 
assessors to be adequate (we considered all other trials 
to be at moderate or high risk of bias).
Data synthesis
Our primary analyses assessed effects of total PUFA, 
omega-6, long chain omega-3, and α-linolenic acid 
(omega-3) separately using random effects meta-
analysis, as dietary interventions are heterogeneous 
by their nature.44 We combined treatment-control 
differences in outcomes across studies by using relative 
risks or mean differences; we converted measures 
using different units to a single unit. We used data 
on change from baseline in each arm with standard 
deviations for continuous outcomes where available 
or endpoint data otherwise.44 We ran sensitivity 
analyses for all primary outcomes by using fixed effect 
meta-analysis, limited to studies at low summary risk 
of bias and at low risk of bias from compliance. We 
did further sensitivity analyses (limiting analyses to 
studies without industry funding, studies registered 
on a trials register if published since 2010, and trials 
that randomised ≥100 participants), subgrouping, and 
funnel plots where a meta-analysis included at least 10 
trials. We noted where data were measured but not fully 
reported to assess potential publication bias, and we 
displayed partially reported data in forest plots to allow 
assessment of consistency with meta-analysis results. 
We used I2 to assess heterogeneity and considered it 
important when it was greater than 50%.45
Effect sizes were interpreted as agreed with WHO 
NUGAG and pre-specified for this set of reviews.36 We 
considered a relative risk below 0.92 or above 1.08 to 
be a relevant clinical effect (0.92-1.08 was considered 
“little or no effect”), and we required a mean difference 
between arms of at least 5% of baseline for a relevant 
clinical effect for continuous measures. Outcome data 
were interpreted using GRADE assessment, drafted by 
LH, and then discussed and agreed with WHO NUGAG 
as elaborated elsewhere.36 Where GRADE suggested 
data of very low quality, we did not interpret effect 
sizes. Where data were of low quality, we used the 
term “may,” and moderate quality evidence warranted 
“probably” in describing effect sizes.
Subgroup analysis
We subgrouped data on the basis of intervention 
type, dose, trial duration, replacement, age, sex, 
baseline diabetes risk categories (general population; 
≥50% without diabetes but with elevated risk due to 
comorbidities such as metabolic syndrome or impaired 
glucose metabolism but not obesity; ≥50% existing 
diagnosis of type 2 diabetes mellitus) and baseline use 
of antidiabetes drugs. We were not able to subgroup by 
baseline intakes or change in omega-3/omega-6 ratio 
as these data were rarely provided. Instead, we added 
a post hoc subgroup comparing “more omega-3 versus 
more omega-6,” from trials with suitable data as, if 
the ratio theory is correct,30 increasing omega-3 at the 
cost of omega-6 would be more beneficial than simply 
boosting omega-3.
Deviations from protocol and post hoc analyses
At the request of the funders, we did an additional 
sensitivity analysis with respect to compliance. Our 
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protocol stated an intention to subgroup by “recent 
publications;” we changed this to run a sensitivity 
analysis including publications before 2010 combined 
with all publications from 2010 onwards with a trials 
registry entry (even if published retrospectively). As our 
funders were particularly interested in effects within 
trials of at least 12 months, we also ran an analysis 
limiting to trials of at least 52 weeks’ duration. At the 
request of reviewers, we assessed small study bias by 
using formal tests (Egger’s test, Begg’s test, Harbord’s 
test, and Peters’ test, each used where appropriate) 
in addition to assessing funnel plot asymmetry, for 
analyses with at least 10 included trials.
Patient and public involvement
We did not involve patients or the public in this 
research at any stage. No patients were involved in 
setting the research question or the outcome measures, 
nor were they involved in developing plans for design 
or implementation of the study. No patients were asked 
to advise on interpretation or writing up of results, but 
we do have plans to disseminate the results of the 
research to the relevant patient community.
Results
Description of studies
Results are summarised here, and a fuller account of 
results (supplementary text) with additional tables, 
forest plots and funnel plots, and details of all 
sensitivity analyses and subgroups, can be found in the 
supplementary materials. Characteristics, risk of bias 
assessments and bibliographic references of included 
studies are detailed in supplementary table A.
We included 83 randomised controlled trials that 
measured at least one of our primary outcomes. These 
83 trials (85 comparison groups) randomised 121 070 
participants. We assessed 10 randomised controlled 
trials as being at low summary risk of bias.46-55 Half 
the trials were conducted in Europe (41), 16 in North 
America, three in South America, 15 in Asia, six in 
Australia, and two across at least two continents. 
Twenty six studies specifically recruited participants 
with diabetes or impaired glucose metabolism (of 
which one recruited people with type 1 diabetes). We 
attempted to contact authors of 52 included trials, 
from whom we received information on methods and/
or results relating to 36 trials (see acknowledgments). 
We found no randomised controlled trials that assessed 
effects of any PUFA on diagnosis of pre-diabetes.
Effects of long chain omega-3
Sixty six trials assessed effects of long chain omega-3, 
of which 10 were at low summary risk of bias. Table 
1 shows the GRADE summary of findings for long 
chain omega-3, with full details of long chain omega-3 
meta-analyses, sensitivity analyses, and subgrouping 
in supplementary tables B to F. Meta-analyses, 
sensitivity analyses, funnel plots, and subgrouping of 
a large body of data suggest that long chain omega-3 
probably has little or no effect on risk of diagnosis 
of type 2 diabetes mellitus (relative risk 1.00, 95% 
confidence interval 0.85 to 1.17; I2=45%; 17 trials; 
58 643 participants, 2196 (3.7%) diabetes diagnoses; 
number need to treat=∞; moderate quality evidence) 
(fig 1). This is confirmed by little or no effect on HbA1c 
(mean difference −0.02%, 95% confidence interval 
−0.07% to 0.04%; I2=49%; 17 comparisons; 32 798 
participants; mean baseline HbA1c 6.5%; moderate 
quality evidence) (fig 2), HOMA-IR (mean difference 
0.06, −0.21 to 0.33; I2=18%; mean baseline HOMA-IR 
4.6; moderate quality evidence) (fig 3), fasting serum 
insulin (mean difference 1.02, −4.34 to 6.37, pmol/L; 
I2=43%; 17 trials; 2077 participants; mean baseline 
insulin 98 pmol/L; low quality evidence) (fig 4), or 
fasting glucose (statistically significant increase in 
glucose from baseline of <1%, mean difference 0.04, 
0.02 to 0.07, mmol/L; I2=0%; 35 156 participants; low 
quality evidence) (fig 5).
Subgrouping results need to be interpreted with 
caution. Subgrouping by dose did not suggest 
statistically significant differences between subgroups 
for any outcomes, but point estimates suggested 
negative outcomes for diagnosis of diabetes, HbA1c, 
HOMA-IR, and glucose at doses above 4.4g/d long chain 
omega-3 (type 2 diabetes mellitus diagnosis relative 
risk 1.86, 0.08 to 44.89; 1 trial with 139 participants; 
HbA1c mean difference 0.61%, −0.44% to 1.67%; 2 
trials with 53 participants; HOMA-IR mean difference 
3.00, −2.78 to 8.78; 1 trial with 37 participants; 
plasma glucose mean 1.12, 0.04 to 2.19, mmol/L; 2 
trials with 69 participants) and smaller negative effects 
for all except HbA1c and fasting glucose at doses from 
2.4 to 4.4 g/d long chain omega-3 (although few trials 
gave >2.4g/d long chain omega-3) (diabetes diagnosis 
relative risk 1.10, 0.80 to 1.51; 4 trials with 3856 
participants; HOMA-IR, mean difference 0.21, −0.37 
to 0.80; 4 trials with 640 participants; fasting insulin 
mean difference 14.31, −2.12 to 30.74, pmol/L; 5 
trials with 737 participants) (full details of subgroup 
analyses by dose are in supplementary tables B to F). 
We looked for effects of duration to ensure that we did 
not miss important health effects not seen in shorter 
trials, but subgrouping did not suggest important 
differences between shorter and longer trials for 
diagnosis of diabetes or other outcomes. We found 
no significant differences between subgroups for type 
of intervention, but studies that provided oily fish or 
other foods were rare, so differences would be difficult 
to see. Effects did not vary by the nutrient replaced by 
long chain omega-3, antidiabetes drug use, or baseline 
glucose metabolism across outcomes.
Effects of α-linolenic acid
Twelve trials assessed effects of α-linolenic acid, one 
of which was at low summary risk of bias. Table 1 
shows GRADE summary of findings for α-linolenic 
acid, and figures 1-5 show meta-analyses. Full details 
of α-linolenic acid analyses, including sensitivity 
analyses and subgrouping, are in supplementary 
tables G to K.
Effects of α-linolenic acid on diagnosis of diabetes 
are uncertain, as the evidence is of very low quality 
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Table 1 | Summary of findings for effects of long chain omega-3 and α-linolenic acid (omega-3) on primary outcomes. High compared with low long 
chain omega-3 (LCn3) and α-linolenic acid (ALA) for prevention or treatment of diabetes
Outcomes
Anticipated absolute effects* (95% CI)
Relative effect 
(95% CI)






Risk with low 
omega-3 fats Risk with high omega-3 fats
Diagnosis of type 2  
diabetes mellitus—LCn3
37 per 1000 37 (32 to 44)  
per 1000
RR 1.00  
(0.85 to 1.17)




LCn3 probably has little or no effect on 
diagnosis of type 2 diabetes.  
Downgraded once for imprecision
Diagnosis of type 2  
diabetes mellitus—ALA
14 per 1000 9 (5 to 19)  
per 1000
RR 0.68  
(0.33 to 1.39)
18 243  
(2 RCTs)
⊕○○○ VERY  
LOWb,e,f
Effect of ALA on diabetes diagnosis is 
uncertain as evidence is of very low 
quality. Downgraded once for  
inconsistency and twice for imprecision
Diagnosis of impaired  
glucose tolerance—LCn3
Not pooled Not pooled Not pooled (0 RCTs) - No RCTs assessed effects of LCn3 
on diagnosis of impaired glucose 
tolerance
Diagnosis of impaired  
glucose tolerance—ALA
Not pooled Not pooled Not pooled (0 RCTs) - No RCTs assessed effects of ALA on  
diagnosis of impaired glucose tolerance
Glycated haemoglobin  
(HbA1c, %)—LCn3
Mean HbA1c  
6.5%
Mean HbA1c 0.02% lower  
(0.07% lower to 0.04% higher)




LCn3 probably has little or no effect on 
glycated haemoglobin. Downgraded 
once for risk of bias
Glycated haemoglobin  
(HbA1c, %)—ALA
Mean HbA1c  
7.0%
Mean HbA1c 0.01% higher  
(0.43% lower to 0.45% higher)




ALA may have little or no effect on  
glycated haemoglobin. Downgraded 
once each for imprecision and risk of bias
Plasma glucose,  
fasting (mmol/L)—LCn3
Mean plasma  
glucose 6.2 mmol/L
Mean plasma glucose 0.04  
(0.02 to 0.07) mmol/L higher




LCn3 may have little or no effect on 
fasting plasma glucose. Downgraded 
once each for risk of bias and  
publication bias
Plasma glucose,  
fasting (mmol/L —ALA
Mean plasma  
glucose 6.2 mmol/L
Mean plasma glucose 0.07 mmol/L 
lower (0.16 lower to 0.02 higher)




ALA probably has little or no effect on 
fasting plasma glucose. Downgraded 
once for risk of bias
Fasting insulin  
(pmol/L)—LCn3
Mean fasting  
insulin 98 pmol/L
Mean fasting insulin 1.02 pmol/L 
higher (4.34 lower to 6.37 higher)




LCn3 may have little or no effect on 
fasting insulin. Downgraded once each 
for risk of bias and imprecision
Fasting insulin  
(pmol/L)—ALA
Mean fasting  
insulin 80 pmol/L
Mean fasting insulin 5.3 pmol/L  
higher (4.68 lower to 15.27 higher)




ALA may increase fasting insulin. 
Downgraded once each for  
imprecision and risk of bias
HOMA-IR—LCn3 Mean HOMA-IR 4.6 Mean HOMA-IR 0.06 higher  
(0.21 lower to 0.33 higher)




LCn3 probably has little or no effect on  
HOMA-IR. Downgraded once for imprecision
HOMA-IR—ALA Mean HOMA-IR 3.4 Mean HOMA-IR 0.1 higher  
(0.5 lower to 0.7 higher)




ALA may have little or no effect on 
HOMA-IR. Downgraded once for  
imprecision and once for risk of bias 
and publication bias combined
HOMA-IR=homoeostatic model assessment for insulin resistance; RCT=randomised controlled trial; RR=risk ratio.
Patient or population: people with or without diabetes at baseline; setting: these are long term trials, so participants lived in the community; intervention: higher omega-3 intake; comparison: 
lower omega-3 intake.
*Risk in intervention group (and its 95% CI) is based on assumed risk in comparison group and relative effect of intervention (and its 95% CI). Note that GRADE describes risk and 95% CI without 
using negative numbers; for example, GRADE states “0.02% lower (0.07 lower to 0.04 higher),” which would normally be described as “–0.02% (−0.07% to 0.04%).”
†High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: we are moderately confident in the effect estimate; the true effect 
is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited; the true effect may be 
substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate 
of effect.
a. Risk of bias: limiting studies to those suggesting good compliance and those at summary risk of bias both suggested greater protection from higher LCn3 intake, although neither was 
statistically significant; these protective effects were entirely due to two small trials (Derosa 2016 and Sawada 2016), and removing them removed heterogeneity and suggestion of any effect. 
Not downgraded.
b. Indirectness: most studies were conducted in industrialised countries, but the data from the 3 RCTs conducted in industrialising countries (Martinez 2014, Wang 2016, Zheng 2016) seem 
consistent. Not downgraded.
c. Imprecision: despite >55 000 participants and >2300 diagnoses, statistical significance is not suggested; 95% CI includes important benefit and important harm. Downgraded once.
d. Publication bias: funnel plot suggests that studies with fewer cases of diabetes in the higher LCn3 arm may be missing, but statistical tests did not confirm this. Not downgraded.
e. Inconsistency: I2>50%. Downgraded once.
f. Imprecision: >18 000 participants, but only 230 diagnoses reported, leading to wide confidence intervals, including very important benefits and harms. Downgraded twice.
g. Risk of bias: although the main analysis suggests no effect of LCn3 on HbA1c, no included trials were at low summary risk of bias, and those at low risk of bias from compliance suggested a 
reduction in HbA1c with LCn3; overall effects not clear. Downgraded once.
h. Indirectness: the largest of the included studies was carried out in China, so data from industrialising countries are well represented. Not downgraded.
i. Imprecision: 178 participants included; very wide confidence intervals did not exclude important benefits or harms. Downgraded once.
j. Risk of bias: main analysis suggests that LCn3 increases plasma glucose, whereas limiting to studies at low summary risk of bias or with low risk of bias from compliance suggests reductions in 
plasma glucose. Downgraded once.
k. Publication bias: although the funnel plot is not definitive, we are aware of potentially important missing data. Downgraded once.
l. Risk of bias: effects in studies at low risk of bias from compliance and in fixed effects analyses are similar to those in the main analysis (suggesting that ALA reduces fasting plasma glucose), but 
no studies were at low summary risk of bias. Downgraded once.
m. Imprecision: data from 648 participants included; important harms and benefits are excluded from the 95% CI; the effect was not statistically significant. Not downgraded.
n. Risk of bias: main analysis suggests little or no effect of LCn3 on fasting insulin, and this is confirmed by fixed effects and low risk of bias from compliance analyses; however, limiting studies to 
those at low summary risk of bias suggests that LCn3 increases fasting insulin substantially (mean difference 25.3 (95% CI 4.1 to 46) pmol/L. Downgraded once.
o. Risk of bias: main analysis suggests a small increase in fasting insulin with ALA, confirmed by fixed effects analysis (neither statistically significant), but smaller effects suggested when studies 
limited to those at low risk of bias from compliance, and no studies were at low summary risk of bias (and no studies were at low risk of bias from allocation concealment). Downgraded once.
p. Imprecision: 95% CI did not exclude important harms. Downgraded once.
q. Risk of bias: main analysis, fixed effects, low risk of compliance, and low summary risk of bias analyses all suggested little or no effect of LCn3 on HOMA-IR. Not downgraded.
r. Publication bias: funnel plot suggests that studies with higher HOMA-IR scores in the LCn3 arm may be missing; however, statistical tests did not confirm this. Not downgraded.
s. Imprecision: 294 participants contributed to this analysis; 95% CI did not exclude important benefit or harm. Downgraded once.
t. Risk of bias and publication bias: no included studies were at low summary risk of bias; the study with data not added to the meta-analysis suggested increased HOMA-IR with greater ALA, 
which may indicate publication bias. Downgraded once between the two risks.
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(relative risk 0.68, 0.33 to 1.39; I2=59%; 2 trials with 
18 243 participants; 230 diabetes diagnoses) (fig 1). 
Other outcomes provided more data, suggesting that 
α-linolenic acid has little or no effect on HbA1c (mean 
difference 0.01%, −0.43% to 0.45%; I2=0%; 3 trials 
with 178 participants; low quality evidence) (fig 2), 
Long chain omega-3
  AlphaOmega: EPA+DHA
  AREDS2 2014
  Burr 2003: DART2
  Clark 2016
  DART fish 1989
  Derosa 2016*
  DO IT: Einvik 2010
  GISSI-P 1999
  JELIS 2007†
  OPAL: Dangour 2010
  ORL: Tatsuno 2013
  Proudman 2015
  REDUCE-IT 2018
  Risk & Prevention 2013
  Sawada 2016
  THIS DIET 2008
  WELCOME 2014
Subtotal (95% CI)
Total events
Test for heterogeneity: τ2=0.03; χ2=29.29, df=16, P=0.02; I2=45%
Test for overall effect: Z=0.05, P=0.96
α-linolenic acid
  AlphaOmega: ALA 2011
  Norwegian: Natvig 1968‡
Subtotal (95% CI)
Total events
Test for heterogeneity: τ2=0.18; χ2=2.45, df=1, P=0.12; I2=59%
Test for overall effect: Z=1.06, P=0.29
Omega-6
  DART fat 1989
  Rose 1965
Subtotal (95% CI)
Total events
Test for heterogeneity: τ2=0.00; χ2=0.30, df=1, P=0.58; I2=0%
Test for overall effect: Z=0.39, P=0.69
Total PUFA
  DART fat 1989
  PREDIMED 2013
  Rose 1965
Subtotal (95% CI)
Total events
Test for heterogeneity: τ2=0.00; χ2=0.41, df=2, P=0.82; I2=0%
Test for overall effect: Z=0.51, P=0.61
Test for subgroup differences:  χ2=1.55, df=3, P=0.67; I2=0%
0.93 (0.71 to 1.21)
1.05 (0.80 to 1.38)
2.46 (0.48 to 12.64)
1.06 (0.07 to 15.60)
3.01 (0.12 to 73.77)
0.19 (0.09 to 0.40)
1.00 (0.42 to 2.36)
1.00 (0.89 to 1.12)
1.41 (0.86 to 2.30)
0.97 (0.49 to 1.91)
2.89 (0.80 to 10.51)
1.86 (0.08 to 44.89)
1.03 (0.74 to 1.45)
1.13 (0.94 to 1.35)
0.28 (0.06 to 1.25)
0.98 (0.06 to 15.25)
1.02 (0.27 to 3.85)
1.00 (0.85 to 1.17)
0.87 (0.67 to 1.14)
0.40 (0.15 to 1.03)
0.68 (0.33 to 1.39)
2.99 (0.12 to 73.34)
0.93 (0.06 to 14.09)
1.52 (0.19 to 12.05)
2.99 (0.12 to 73.34)
1.07 (0.80 to 1.43)
0.93 (0.06 to 14.09)
1.08 (0.81 to 1.43)








Risk ratio (95% CI)
M-H, random





































































































A IB C D E F G H
Risk of bias
Fig 1 | Effect of long chain omega-3, α-linolenic acid, omega-6, and total polyunsaturated fatty acids (PUFA), on new diagnosis of diabetes. *Verified: 
see author response. †Reported as rise in blood sugar. ‡Diabetes excluded at baseline. Risk of bias key: A=random sequence generation (selection 
bias); B=Allocation concealment (selection bias); C=blinding of participants and personnel (performance bias); D=blinding of outcome assessment 
(detection bias); E=incomplete outcome data (attrition bias); F=selective reporting (reporting bias); G=attention; H=compliance; I=other bias
 on 22 A
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Long chain omega-3
  Balfego 2016
  Bonnema 1995*
  Connor 1993
  Dasarathy 2015
  Deslypere 1992
  DO IT: Einvik 2010
  EPE-A 2014†
  IFOMS: Sirtori 1997
  JELIS 2007‡
  JELIS 2007§
  Krebs 2006¶
  Martinez 2014**
  Mita 2007
  Niki 2016
  ORIGIN 2012††
  Risk & Prevention 2013
  Sasaki 2012
  Sawada 2016
  Tande 2016
  Veleba 2015‡‡
  Veleba 2015‡‡
  Wang 2016
  Witte 2012
  Zheng 2016
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00; χ2=31.67, df=16, P=0.01; I2=49%
Test for overall effect: Z=0.59, P=0.55
α-linolenic acid
  HERO: Tapsell 2009
  Tapsell 2004
  Zheng 2016
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00; χ2=0.74, df=2, P=0.69; I2=0%
Test for overall effect: Z=0.05, P=0.96
Omega-6
  Dullaart 1992
  Heine 1989
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00; χ2=0.00, df=1, P=1.00; I2=0%
Test for overall effect: Z=0.00, P=1.00
Total PUFA
  Dullaart 1992
  Heine 1989
  PREDIMED 2013§§
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00; χ2=0.03, df=2, P=0.99; I2=0%
Test for overall effect: Z=0.31, P=0.76
Test for subgroup differences:  χ2=0.16, df=3, P=0.98; I2=0%
0.20 (-0.08 to 0.48)
Not estimable
0.70 (-5.04 to 6.44)
0.60 (-0.53 to 1.73)
0.02 (-0.28 to 0.32)
-0.20 (-0.32 to -0.08)
Not estimable
0.16 (-0.14 to 0.46)
0.10 (0.02 to 0.18)
0.00 (-0.02 to 0.02)
Not estimable
Not estimable
0.41 (-0.14 to 0.96)
0.00 (-0.51 to 0.51)
Not estimable
0.00 (-0.05 to 0.05)
-0.20 (-0.94 to 0.54)
-0.20 (-0.35 to -0.05)
0.02 (-0.47 to 0.51)
Not estimable
Not estimable
-0.11 (-0.69 to 0.47)
-0.10 (-0.25 to 0.05)
-0.10 (-1.01 to 0.81)
-0.02 (-0.07 to 0.04)
0.40 (-0.59 to 1.39)
-0.08 (-0.67 to 0.51)
-0.10 (-1.02 to 0.82)
0.01 (-0.43 to 0.45)
0.00 (-1.18 to 1.18)
0.00 (-1.94 to 1.94)
0.00 (-1.01 to 1.01)
0.00 (-1.18 to 1.18)
0.00 (-1.94 to 1.94)
0.10 (-0.45 to 0.65)
0.08 (-0.41 to 0.56)









(95% CI) IV, random
Mean difference
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Risk of bias
Fig 2 | Effect of long chain omega-3, α-linolenic acid, omega-6, and total polyunsaturated fatty acids (PUFA) on glycated haemoglobin (%). *Units 
unclear. †Median change from baseline (zero in both arms). ‡In participants with impaired glucose metabolism at baseline. §In participants 
normoglycaemic at baseline. ¶Geometric means. **Change in medians. ††Medians only provided. ‡‡Median change. §§Barcelona hospital cohort 
at 5 years, Casas 2016. Risk of bias key: A=random sequence generation (selection bias); B=Allocation concealment (selection bias); C=blinding 
of participants and personnel (performance bias); D=blinding of outcome assessment (detection bias); E=incomplete outcome data (attrition bias); 
F=selective reporting (reporting bias); G=attention; H=compliance; I=other bias
 on 22 A
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HOMA-IR (mean difference 0.10, −0.50 to 0.70; I2=0%; 
4 trials with 294 participants; baseline HOMA-IR 3.4; 
low quality evidence) (fig 3), and fasting glucose (mean 
difference −0.07, −0.16 to 0.02, mmol/L glucose; 
I2=0%; 7 trials with 648 participants; moderate 
quality evidence) (fig 5). However, α-linolenic acid may 
increase fasting insulin (mean difference 5.3, −4.68 to 
15.27, pmol/L; I2=0%; 6 trials with 469 participants; 
increase of 7% from 80 pmol/L baseline; low quality 
evidence) (fig 4).
Omega-3 versus omega-6
We considered the subgroup of studies that replaced 
omega-6 with omega-3 (either long chain omega-3 or 
Long chain omega-3
  Balfego 2016
  Caldwell 2011
  Clark 2016
  Dasarathy 2015
  de Luis 2016
  Derosa 2009
  Derosa 2016
  EPE-A 2014*
  Krebs 2006†
  Lalia 2015
  OPTILIP 2006†
  Sawada 2016‡
  SMART Tapsell 2013
  Sofi 2010
  Spadaro 2008
  Tardivo 2015
  Zheng 2016
Subtotal (95% CI)
Test for heterogeneity: τ2=0.04; χ2=14.55, df=12, P=0.27; I2=18%
Test for overall effect: Z=0.43, P=0.66
α-linolenic acid
  MENU: Rock 2016
  Nigam 2014
  OPTILIP 2006†
  Zheng 2016
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00; χ2=1.00, df=2, P=0.61; I2=0%
Test for overall effect: Z=0.32, P=0.75
Omega-6
  Nigam 2014
Subtotal (95% CI)
Test for heterogeneity: Not applicable
Test for overall effect: Z=3.23, P<0.001
Total PUFA
  PREDIMED 2013§
Subtotal (95% CI)
Test for heterogeneity: Not applicable
Test for overall effect: Z=1.22, P=0.22
Test for subgroup differences:  χ2=11.64, df=3, P=0.009; I2=74.2%
-0.30 (-2.42 to 1.82)
2.60 (-1.76 to 6.96)
0.42 (-0.03 to 0.88)
3.00 (-2.78 to 8.78)
0.20 (-0.17 to 0.57)
0.10 (-2.26 to 2.46)
-2.80 (-7.64 to 2.04)
Not estimable
Not estimable
-0.58 (-2.04 to 0.88)
Not estimable
Not estimable
0.10 (-0.19 to 0.39)
-1.00 (-4.90 to 2.90)
-1.18 (-2.62 to 0.26)
-0.40 (-1.37 to 0.57)
-1.78 (-3.79 to 0.23)
0.06 (-0.21 to 0.33)
0.00 (-0.83 to 0.83)
0.40 (-0.56 to 1.36)
Not estimable
-0.72 (-2.84 to 1.40)
0.10 (-0.50 to 0.70)
1.50 (0.59 to 2.41)
1.50 (0.59 to 2.41)
-0.34 (-0.88 to 0.20)
-0.34 (-0.88 to 0.20)









(95% CI) IV, random
Mean difference
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Risk of bias
Fig 3 | Effect of long chain omega-3, α-linolenic acid, omega-6, and total polyunsaturated fatty acids (PUFA) on homoeostatic model assessment for 
insulin resistance (HOMA-IR) score. *Median change from baseline. †Geometric means. ‡Medians. §Reus subcohort, 2 year data. Risk of bias key: 
A=random sequence generation (selection bias); B=Allocation concealment (selection bias); C=blinding of participants and personnel (performance 
bias); D=blinding of outcome assessment (detection bias); E=incomplete outcome data (attrition bias); F=selective reporting (reporting bias); 
G=attention; H=compliance; I=other bias
 on 22 A
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Long chain omega-3
  Balfego 2016
  Caldwell 2011
  Clark 2016
  de Luis 2016
  Derosa 2009*
  Derosa 2016*
  DO IT: Einvik 2010
  Finnegan 2003
  IFOMS: Sirtori 1997
  Krebs 2006†
  Lalia 2015
  Martinez 2014‡
  Sawada 2016
  SMART Tapsell 2013
  Sofi 2010
  Tande 2016
  Tardivo 2015
  THIS DIET 2008§
  WELCOME 2014
  Zheng 2016
Subtotal (95% CI)
Test for heterogeneity: τ2=35.10; χ2=28.03, df=16, P=0.03; I2=43%
Test for overall effect: Z=0.37, P=0.71
α-linolenic acid
  Baxheinrich 2012
  Finnegan 2003
  HERO: Tapsell 2009
  MENU: Rock 2016
  Nigam 2014*
  OPTILIP 2006†
  Zheng 2016
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00; χ2=4.60, df=5, P=0.47; I2=0%
Test for overall effect: Z=1.04, P=0.30
Omega-6
  Heine 1989
  MUFFIN Miller 2016
  Nigam 2014*
Subtotal (95% CI)
Test for heterogeneity: τ2=7.09; χ2=8.68, df=2, P=0.01; I2=77%
Test for overall effect: Z=0.84, P=0.40
Total PUFA
  Heine 1989
  MUFFIN Miller 2016
  PREDIMED 2013¶
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00; χ2=0.16, df=2, P=0.93; I2=0%
Test for overall effect: Z=0.12, P=0.90
Test for subgroup differences:  χ2=1.32, df=3, P=0.72; I2=0%
-4.17 (-45.01 to 36.67)
51.39 (-30.46 to 133.24)
25.56 (3.14 to 47.98)
3.47 (-7.71 to 14.65)
2.09 (-33.65 to 37.83)
-50.00 (-175.72 to 75.72)
-18.80 (-35.84 to -1.76)
10.27 (-10.71 to 31.25)
-7.70 (-21.07 to 5.67)
Not estimable
-11.81 (-48.25 to 24.63)
Not estimable
2.78 (-4.98 to 10.54)
0.41 (-1.86 to 2.68)
11.80 (-11.27 to 34.87)
3.56 (-11.98 to 19.10)
-14.00 (-38.20 to 10.20)
Not estimable
25.70 (3.45 to 47.95)
-45.10 (-83.39 to -6.81)
1.02 (-4.34 to 6.37)
-6.80 (-26.59 to 12.99)
11.25 (-7.69 to 30.19)
25.00 (-7.22 to 57.22)
5.55 (-15.70 to 26.80)
13.20 (-19.07 to 45.47)
Not estimable
-17.40 (-59.44 to 24.64)
5.30 (-4.68 to 15.27)
0.00 (-19.24 to 19.24)
-7.00 (-40.32 to 26.32)
55.60 (20.96 to 90.24)
14.71 (-19.81 to 49.24)
0.00 (-19.24 to 19.24)
-7.00 (-40.32 to 26.32)
0.00 (-11.99 to 11.99)
-0.60 (-10.33 to 9.14)









(95% CI) IV, random
Mean difference
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Risk of bias
Fig 4 | Effect of long chain omega-3, α-linolenic acid, omega-6, and total polyunsaturated fatty acids (PUFA) on fasting serum insulin (pmol/L). 
*Reported SDs seemed to be SEs, so converted. †Geometric means. ‡Change in median. §Change, no measure of variance supplied. ¶Reus 
subcohort, 2 year data. Risk of bias key: A=random sequence generation (selection bias); B=Allocation concealment (selection bias); C=blinding 
of participants and personnel (performance bias); D=blinding of outcome assessment (detection bias); E=incomplete outcome data (attrition bias); 
F=selective reporting (reporting bias); G=attention; H=compliance; I=other bias
 on 22 A
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Long chain omega-3
  Balfego 2016
  Bonnema 1995
  Clark 2016
  Connor 1993
  Dasarathy 2015*
  de Luis 2016
  DeFina 2010
  Derosa 2009†
  Derosa 2011†
  Derosa 2016†
  DIPP: Tokudome 2015
  DO IT: Einvik 2010
  Ebrahimi 2009
  EPE-A 2014‡
  Finnegan 2003
  IFOMS: Sirtori 1997
  JELIS 2007§
  JELIS 2007¶
  Krebs 2006**
  Lalia 2015
  Martinez 2014††
  Niki 2016
  Nodari 2011 HF
  OFAMI: Nilsen 2001
  OPTILIP 2006**
  Patch 2005
  Risk & Prevention 2013
  Sasaki 2012
  SHOT: Eritsland 1996
  SMART: Tapsell 2013
  Smith 2015
  Sofi 2010
  Tande 2016
  Tardivo 2015
  THIS DIET 2008‡‡
  Veleba 2015§§
  Veleba 2015§§
  Wang 2016
  WELCOME 2014
  Witte 2012
  Zheng 2016
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00; χ2=29.45, df=33, P=0.64; I2=0%
Test for overall effect: Z=3.36, P<0.001
α-linolenic acid
  Baxheinrich 2012
  Dodin 2005
  Finnegan 2003
  HERO: Tapsell 2009¶¶
  MENU: Rock 2016
  Nigam 2014
  OPTILIP 2006**
  Zheng 2016
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00; χ2=4.69, df=6, P=0.58; I2=0%
Test for overall effect: Z=1.51, P=0.13
Omega-6
  Ferrara 2000†
  Heine 1989
  Nigam 2014
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00; χ2=0.07, df=2, P=0.97; I2=0%
Test for overall effect: Z=0.62, P=0.53
Total PUFA
  Ferrara 2000
  Heine 1989
  PREDIMED 2013***
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00; χ2=0.26, df=2, P=0.88; I2=0%
Test for overall effect: Z=0.50, P=0.62
Test for subgroup differences:  χ2=7.18, df=3, P=0.07; I2=58.2%
-0.03 (-0.78 to 0.72)
0.60 (-2.82 to 4.02)
0.00 (-0.48 to 0.48)
0.33 (-7.02 to 7.68)
1.50 (0.25 to 2.75)
0.00 (-0.31 to 0.31)
-0.03 (-0.22 to 0.16)
0.00 (-1.29 to 1.29)
-0.17 (-0.87 to 0.53)
-1.08 (-2.26 to 0.10)
-0.13 (-0.50 to 0.24)
-0.20 (-0.46 to 0.06)
0.23 (-0.99 to 1.45)
Not estimable
-0.14 (-0.36 to 0.08)
0.23 (-0.17 to 0.63)
0.06 (-0.09 to 0.21)
0.05 (0.02 to 0.08)
Not estimable
-0.10 (-0.80 to 0.60)
Not estimable
0.40 (-0.83 to 1.63)
-0.30 (-0.62 to 0.02)
0.10 (-0.22 to 0.42)
Not estimable
0.00 (-0.28 to 0.28)
0.09 (0.01 to 0.17)
0.11 (-1.13 to 1.35)
-0.07 (-0.29 to 0.15)
-0.10 (-0.43 to 0.23)
0.20 (-0.06 to 0.46)
-0.22 (-3.66 to 3.22)
0.01 (-0.14 to 0.16)




0.01 (-0.88 to 0.90)
0.00 (-0.80 to 0.80)
0.10 (-0.14 to 0.34)
0.24 (-0.78 to 1.26)
0.04 (0.02 to 0.07)
-0.09 (-0.48 to 0.30)
-0.06 (-0.17 to 0.05)
-0.09 (-0.34 to 0.17)
1.30 (-0.33 to 2.93)
0.00 (-0.25 to 0.25)
-0.30 (-0.65 to 0.05)
Not estimable
-0.06 (-1.04 to 0.92)
-0.07 (-0.16 to 0.02)
-0.04 (-0.74 to 0.66)
-0.30 (-2.24 to 1.64)
-0.10 (-0.43 to 0.23)
-0.09 (-0.39 to 0.20)
-0.04 (-0.19 to 0.11)
-0.30 (-2.24 to 1.64)
0.17 (-0.77 to 1.11)
-0.04 (-0.18 to 0.11)







(95% CI) IV, random
Mean difference
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Risk of bias
Fig 5 | Effect of long chain omega-3, α-linolenic acid, omega-6, and total polyunsaturated fatty acids (PUFA) on fasting serum or plasma glucose 
(mmol/L). *Numbers verified. †Reported SDs seemed to be SEs, so converted. ‡Median change. §In participants with impaired glucose metabolism 
at baseline. ¶In participants normoglycaemic at baseline. **Geometric means. ††Change in median. ‡‡Change (no SDs supplied). §§Median 
change; data reported as mean and interquartile range. ¶¶Data verified. ***Barcelona hospital cohort at 5 years, Casas 2016. Risk of bias key: 
A=random sequence generation (selection bias); B=Allocation concealment (selection bias); C=blinding of participants and personnel (performance 
bias); D=blinding of outcome assessment (detection bias); E=incomplete outcome data (attrition bias); F=selective reporting (reporting bias); 
G=attention; H=compliance; I=other bias
 on 22 A
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α-linolenic acid; see supplementary tables L-N). If the 
theory that omega-3 and omega-6 fats have opposing 
roles is correct, we would expect to see strong effects 
when omega-3 replaces dietary omega-6. However, the 
data were weak, with limited events, no trials at low 
summary risk of bias, and wide confidence intervals, 
so effects of replacing omega-6 with omega-3 fats on 
diabetes diagnosis and fasting insulin were unclear. We 
found little or no effect for omega-3 versus omega-6 on 
HbA1c (mean difference −0.15%, −0.24% to −0.06%; 
I2=0%; 6 trials with 841 participants), HOMA-IR (mean 
difference −0.23, −1.35 to 0.88; I2=60%; 6 trials 
with 328 participants), and fasting glucose (mean 
difference −0.03, −0.11 to 0.05, mmol/L; I2=10%; 14 
comparisons with 1641 participants).
Effects of omega-6
Eleven trials (none at low summary risk of bias) 
assessed effects of increasing omega-6. Figures 1 
to 5 show meta-analyses, table 2 shows the GRADE 
summary of findings, and full details of omega-6 
meta-analyses, including sensitivity analyses, are in 
supplementary tables O-T.
Effects of omega-6 fats on type 2 diabetes mellitus 
diagnosis (only three diabetes diagnoses included) (fig 
1), fasting insulin (mean difference 14.71, −19.81 to 
49.24, pmol/L; I2=77%; 124 participants in 3 trials) 
(fig 4), HOMA-IR (mean difference 1.50, 0.59 to 2.41; 1 
trial with 60 participants; mean baseline HOMA-IR 2.4) 
(fig 3), and plasma glucose (mean difference −0.09, 
−0.39 to 0.20, mmol/L; I2=0%; 134 participants in 3 
trials) (fig 5) were unclear, as quality of evidence was 
very low. Omega-6 fats may have little or no effect on 
HbA1c (mean difference 0.00%, −1.01% to 1.01%; 
I2=0%; 64 participants in 2 trials; mean baseline HbA1c 
7.9%; low quality evidence) (fig 2).
Effects of total PUFA
We included eight randomised controlled trials that 
aimed to increase total PUFA or both omega-3 and 
Table 2 | Summary of findings for effects of omega-6 on primary outcomes. High compared with low omega-6 fats for prevention or treatment of 
diabetes
Outcomes





Certainty of the  
evidence (GRADE)† Comments
Risk with low 
omega-6 fats
Risk with high  
omega-6 fats
Diagnosis of type 2 
diabetes mellitus
1 per 1000 1 (0 to 12) per 1000 RR 1.52  
(0.19 to 12.05)
2087 (2 RCTs) ⊕○○○ VERY LOWa,b,c Effect of omega-6 fats on diagnoses of 
type 2 diabetes mellitus is unclear as 
quality of evidence is very low.  
Downgraded once for risk of bias and 
twice for imprecision
Diagnosis of impaired 
glucose tolerance




Mean HbA1c 7.9% Mean HbA1c 0.0% 
(1.01% lower to 
1.01% higher)
- 64 (2 RCTs) ⊕⊕○○ LOWd,e Omega 6 fat may have little or no effect 
on glycated haemoglobin. Downgraded 
once each for imprecision and risk of bias




Mean plasma glucose 
0.09 lower (0.39 lower 
to 0.20 higher)
- 134 (3 RCTs) ⊕○○○ VERY LOWf,g,h Effect of omega-6 fats on plasma glucose 
is unclear as quality of evidence is very 
low. Downgraded once each for imprecision, 
risk of bias, and publication bias
Insulin,  
fasting (pmol/L)
Mean insulin 55.4 
pmol/L
Mean insulin 14.7 
higher (19.8 lower to 
49.2 higher)
- 124 (3 RCTs) ⊕○○○ VERY LOWi,j,k Effect of omega-6 on fasting insulin is 
unclear as data are of very low quality. 
Downgraded once each for imprecision, 
inconsistency, and risk of bias
HOMA-IR Mean HOMA-IR 2.4 Mean HOMA-IR 1.5 
(0.59 to 2.41) higher
- 60 (1 RCT) ⊕○○○ VERY LOWl,m Effect of increasing omega-6 on HOMA-IR 
is unclear as data are of very low quality. 
Downgraded once for risk of bias and 
twice for indirectness
HOMA-IR=homoeostatic model assessment for insulin resistance; RCT=randomised controlled trial; RR=risk ratio.
Patient or population: people with and without diabetes; setting: these are long term trials, so participants live in the community; intervention: high omega-6 fats; comparison: low omega-6 fats.
*Risk in intervention group (and its 95% CI) is based on assumed risk in comparison group and relative effect of intervention (and its 95% CI). Note that GRADE describes risk and 95% CI without 
using negative numbers; for example, GRADE states “0.02% lower (0.07 lower to 0.04 higher),” which would normally be described as “–0.02% (−0.07% to 0.04%).”
†High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: we are moderately confident in the effect estimate; the true effect 
is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited; the true effect may be 
substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate 
of effect.
a. Risk of bias: effect size did not differ with fixed effects analysis, but neither included study was at low risk of bias from compliance, at low summary risk of bias, or at low risk of bias from 
allocation concealment. Downgraded once.
b. Indirectness: both studies were carried out in the UK, in men, and more than 25 years ago. Not downgraded.
c. Imprecision: 2087 randomised participants, but only 3 diagnoses reported; very limited data available. Downgraded twice.
d. Risk of bias: effect size did not differ with fixed effects analysis, but neither included study was at low summary risk of bias; 1 was at low risk of bias from allocation concealment, and 1 was at 
low risk of bias from compliance problems (both suggesting no effect of omega-6 on HbA1c). Downgraded once.
e. Imprecision: data included from 252 participants in 3 RCTs; confidence intervals do not exclude important harm. Downgraded once.
f. Risk of bias: effect size did not differ with fixed effects analysis; none of the 3 included trials was at low risk from allocation concealment or at low summary risk of bias; 1 trial was at low risk of 
bias from compliance, suggesting a small (but not statistically significant) fall in glucose with more omega-6. Downgraded once.
g. Imprecision: 134 included participants from 3 trials; 95% CI include both important benefits and harms. Downgraded once.
h. Publication bias: we are aware of a further 3 trials that measured glucose but did not report it in a way that could be included in meta-analysis. Downgraded once.
i. Risk of bias: small non-statistically significant increase in insulin with omega-6 seen also in fixed effects analysis; no trials were at low summary risk of bias or at low risk of bias from allocation 
concealment; 1 trial at low risk of bias from compliance suggested no effect of omega-6 on insulin. Downgraded once.
j. Inconsistency: I2=82%. Downgraded once.
k. Imprecision: data from 124 participants (2 RCTs); 95% CI included important harms and benefits. Downgraded once.
l. Risk of bias: the single study was not at low risk from compliance, allocation concealment, or summary risk of bias. Downgraded once.
m. Indirectness: small single study only. Downgraded twice.
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omega-6 fats, none of which was at low summary risk 
of bias. Table 3 shows the GRADE summary of findings, 
figures 1 to 5 show meta-analyses, and full details of 
PUFA analyses are in supplementary tables U-Z. Effects 
of increasing total PUFA on risk of type 2 diabetes 
mellitus (fig 1) and HOMA-IR (fig 3) were unclear, as 
the evidence was of very low quality. Increasing total 
PUFA may make little or no difference to HbA1c (mean 
difference 0.08%, −0.41% to 0.56%; I2=0%; 3 trials 
with 172 participants; mean baseline HbA1c 8.6%) (fig 
2), fasting insulin (mean difference −0.60, −10.33 to 
9.14, pmol/L; I2=0%; 3 trials with 157 participants; 
mean baseline insulin 62 pmol/L) (fig 4), or fasting 
glucose (mean difference −0.04, −0.18 to 0.11, 
mmol/L; I2=0%; 3 trials with 182 participants; mean 
baseline fasting glucose 8.1 mmol/L; low quality data) 
(fig 5).
Secondary outcomes
Secondary outcomes were planned as serum lipids, 
adiposity, all cause mortality, and mortality due to 
diabetes. However, as effects of omega-3, omega-6, 
and total PUFA on mortality, lipids, and adiposity 
were formally systematically reviewed in sister reviews 
assessing effects in randomised controlled trials of at 
least 12 months’ duration,29 33 34 secondary outcomes 
for this review are reported only in supplementary 
tables M, N, T, and Z. We found no data on mortality 
due to diabetes.
Discussion
Long chain omega-3 fats seem to have little or no effect 
on type 2 diabetes or measures of glucose metabolism 
including insulin resistance (measured using HOMA-
IR), glycated haemoglobin (HbA1c), fasting glucose, or 
insulin. Although effects of α-linolenic acid, omega-6, 
and total PUFA on diagnosis of diabetes were unclear 
(as the evidence was of very low quality), we found 
little or no effect on measures of glucose metabolism, 
except that increasing α-linolenic acid may increase 
fasting insulin (low quality evidence). We found no 
evidence that the omega-3/omega-6 ratio is important 
to type 2 diabetes mellitus or glucose metabolism.
Strengths and limitations of study
Strengths of this review include its large size (including 
81 trials, with more than 95 000 randomised 
participants with and without diabetes, from around 
the world), and searching of multiple databases. 
Creation of a dataset of randomised controlled trials 
regardless of outcomes and contacting authors to 
request relevant data allowed inclusion of data that 
Table 3 | Summary of findings for effects of increasing total polyunsaturated fatty acids (PUFA) on primary outcomes. High compared with low total 
polyunsaturated fats for prevention or treatment of diabetes
Outcomes
Anticipated absolute effects* (95% CI)
Relative effect 
(95% CI)
No of  
participants 
(studies)
Certainty of evidence 
(GRADE)† Comments
Risk with low 
PUFA Risk with high PUFA
Diagnosis of type 2  
diabetes mellitus
37 per 1000 40 per 1000  
(30 to 53)
RR 1.08  
(0.81 to 1.43)
4481 (3 RCTs) ⊕○○○ VERY LOWa,b Effect of increasing total PUFA on risk of 
diabetes diagnosis is unclear as evidence was 
of very low quality. Downgraded once for risk 
of bias and twice for imprecision
Diagnosis of impaired  
glucose tolerance
0 per 1000 0 per 1000 (0 to 0) Not  
estimable
(0 RCTs) - No RCTs assessed effect of total PUFA on 
diagnosis of impaired glucose tolerance




Mean HbA1c, 0.08%  
higher (0.41% lower to  
0.56% higher)
- 172 (3 RCTs) ⊕⊕○○ LOWc,d Increasing total PUFA may make little or 
no difference to glycated haemoglobin. 
Downgraded once each for imprecision and 
risk of bias





Mean plasma glucose  
0.04 mmol/L lower  
(0.18 lower to 0.11 higher)
- 182 (3 RCTs) ⊕⊕○○ LOWe,f Increasing total PUFA may make little or no 
difference to plasma glucose. Downgraded 





Mean insulin 0.6 pmol/L  
lower (10.33 lower  
to 9.14 higher)
- 157 (3 RCTs) ⊕⊕○○ LOWc,d Increasing total PUFA may make little or no 
difference to fasting insulin. Downgraded 
once each for imprecision and risk of bias
HOMA-IR Mean  
HOMA-IR 1.8
Mean HOMA-IR 0.34  
lower (0.88 lower  
to 0.2 higher)
- 93 (1 RCT) ⊕○○○ VERY LOWg,h,i Effect of increasing total PUFA on HOMA-IR 
is unclear, as evidence is of very low quality. 
Downgraded once each for imprecision, 
indirectness and risk of bias
HOMA-IR=homoeostatic model assessment for insulin resistance; RCT=randomised controlled trial; RR=risk ratio.
Patient or population: people with and without diabetes; setting: these are long term trials, so participants live in the community; intervention: high total PUFA; comparison: low total PUFA.
*Risk in intervention group (and its 95% CI) is based on assumed risk in comparison group and relative effect of intervention (and its 95% CI). Note that GRADE describes risk and 95% CI without 
using negative numbers; for example, GRADE states “0.02% lower (0.07 lower to 0.04 higher),” which would normally be described as “–0.02% (−0.07% to 0.04%).”
†High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: we are moderately confident in the effect estimate; the true effect 
is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited; the true effect may be 
substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate 
of effect.
a. Risk of bias: no studies were at low summary risk of bias or at low risk from compliance problems. Downgraded once.
b. Imprecision: 4481 participants in 3 RCTs, 175 diagnoses; 95% CI did not exclude important benefits or harms. Downgraded twice.
c. Risk of bias: lack of effect consistent in fixed effects analysis, and sensitivity analyses on concentration, but no included trials were at low summary risk of bias. Downgraded once.
d. Imprecision: 95% CI does not exclude important harms or benefits. Downgraded once.
e. Risk of bias: effect did not alter with fixed effects analysis; the single study at low risk from compliance suggested a small reduction in glucose with increased PUFA, but no trials were at low 
summary risk of bias or had low risk from allocation concealment. Downgraded once.
f. Imprecision: data based on 182 participants in 3 trials; 95% CI does not exclude important benefits or harms. Downgraded once.
g. Imprecision: data reflect a single study in 93 participants (a small proportion of the participants in the whole study); 95% CI does not exclude important harm. Downgraded once.
h. Risk of bias: effect not altered in fixed effects analysis, but the single study was not at low risk from summary risk of bias or compliance. Downgraded once.
i. Indirectness: subgroup of a single trial reported. Downgraded once.
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would otherwise have been missed or remained 
unpublished (particularly for diagnosis of diabetes 
in populations not at high risk) and also allowed us 
to identify the extent and sometimes the import of 
missing data. Our data make it clear that missing data 
may be a serious threat to our understanding in this 
review. For example, we included 48 comparisons 
in the meta-analysis assessing effects of long chain 
omega-3 on plasma glucose, but we are aware of 15 
further trials with data that could not be included. 
This volume of missing data could considerably alter 
the findings of the review. Missing data sprang from 
trials providing some information but not offering 
useable variance data, trials unbalanced at baseline, 
provision of medians or geometric means, and trials 
that clearly assessed our outcomes but provided no 
useable data. Weaknesses of the review include limited 
data on effects of increasing α-linolenic acid, omega-6, 
and total PUFA, as well as potentially serious risk of 
bias in many included trials. We did not find evidence 
of the importance of the omega-3/omega-6 ratio, but 
limiting to trials comparing increased omega-3 fats 
with increased omega-6 limits the quantity of data 
(reducing our power to see any effect) and the quality 
(only one of the included trials was at low summary 
risk of bias) of the available information. Additionally, 
doses of omega-6 were often small, so we could be 
missing important effects of the ratio. Long chain 
omega-3 results included mostly supplementation 
trials, which precluded fair assessment of effects 
of increasing oily fish consumption. Only 10 of 83 
included randomised controlled trials were at low 
summary risk of bias. As poorly concealed allocation is 
associated with a 40% greater effect size,56 and lack of 
blinding with additional bias,57 58 caution is needed in 
interpreting small effects in weaker trials.
Dose and duration effects (subgrouping)
Although subgrouping by dose did not suggest 
statistically significant differences between subgroups 
for any outcome, point estimates suggested worse 
outcomes for all outcomes at doses above 4.4 g/d and 
some outcomes at doses above 2.4 g/d long chain 
omega-3, suggesting that high doses may have negative 
effects in diabetes (but this should be interpreted 
with caution). We found no suggestions of greater 
positive or negative effects of long chain omega-3 at 
longer durations, by replacement, by risk of diabetes, 
or by intervention type such as dietary advice, food 
supplements, or supplementary capsules, as would be 
expected if different matrix effects were present.59
Comparison with other studies
The most recent Cochrane review assessing effects 
of omega-3 on diabetes included 23 randomised 
controlled trials that randomised 1075 adults with 
diagnosed diabetes and had a mean duration of nine 
weeks.31 It suggested that increasing omega-3 reduced 
triglycerides, increased low density lipoprotein 
cholesterol, and did not alter HbA1c, fasting glucose, 
insulin, or body weight. It found insufficient events to 
assess mortality, results reiterated by a later review.32 
Our review updates, extends, and partially confirms 
these findings, but no previous reviews of randomised 
controlled trials have assessed effects of increasing 
omega-3 on diagnosis of diabetes. Results of cohort 
study results are mixed, with some suggesting 
protection, some harm, and others no effect of omega-3, 
or fish, on risk of diabetes.60-62 A systematic review of 
recent randomised controlled trial and observational 
data found inconclusive evidence for associations 
between omega-3 and type 2 diabetes mellitus.63 
Geographical differences may exist, relating to fat 
type, fat quality, or background intake,28 but these 
were not assessed in our review. Systematic review of 
observational studies suggests that higher circulating 
α-linolenic acid was non-significantly associated with 
lower risk of diabetes (relative risk per 0.1% total fatty 
acid 0.90, 0.80 to 1.00), and circulating concentration 
(relative risk per 3% total fatty acids 0.94, 0.75 to 1.17) 
and intake (relative risk per 250 mg/d 1.04, 0.97 to 
1.10) of eicosapentaenoic acid and docosahexaenoic 
acid were not associated with risk of diabetes.64
Although we found little suggestion that long chain 
omega-3 harms glucose metabolism except perhaps 
at very high doses, the recently completed ASCEND 
trial reported complications of diabetes in 33 of 7740 
participants with type 2 diabetes mellitus taking 0.84 
g/d long chain omega-3 over more than seven years and 
20 of 7740 taking placebo (relative risk 1.65, 0.95 to 
2.87).55 We hope that further details from this study of 
effects on glucose metabolism will be published soon.
We found limited data from randomised controlled 
trials on effects of omega-6 or total PUFA on diagnosis of 
diabetes. A consortium of 20 prospective cohort studies 
included 39 740 adults from 10 countries and found 
that higher biomarker linoleic acid was associated with 
35% lower risk of type 2 diabetes mellitus (relative risk 
per interquartile range 0.65, 0.60 to 0.72).65 Data from 
the European Prospective Investigation into Cancer 
and Nutrition study associated both α-linolenic acid 
(hazard ratio per standard deviation 0.93, 0.88 to 0.98) 
and linoleic acid biomarkers (0.80, 0.77 to 0.83) with 
lower risk of type 2 diabetes mellitus; arachidonic acid 
and long chain omega-3 were not associated, but other 
omega-6 fatty acids were associated with higher risk.66 
Replacing saturated fat with PUFA was associated with 
decreased total cholesterol and low density lipoprotein 
cholesterol, without associations with triglycerides, 
insulin, or glucose in another systematic review.63
Conclusions and policy implications
No convincing evidence suggests that altering 
intakes of long chain omega-3, α-linolenic acid, 
omega-6, or total PUFA alters glucose metabolism or 
risk of diabetes. Supplemental long chain omega-3 
should not be encouraged for prevention or treatment 
of diabetes. Where supplementary long chain omega-3 
is used to reduce triglyceride concentrations, or people 
with or at risk of type 2 diabetes mellitus choose to take 
supplementary long chain omega-3, doses below 4.4 
g/d should be encouraged.
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Unanswered questions and future research
Further randomised controlled trials of effects of 
α-linolenic acid, omega-6, oily fish, and total PUFA 
with rigorous methods (larger sample sizes, adequate 
and well reported allocation concealment and 
blinding, at least 12 months’ duration) on diagnosis of 
diabetes and measures of glucose metabolism would 
be helpful.
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